MCID: HDG012
MIFTS: 73

Hodgkin Lymphoma malady

Categories: Genetic diseases, Rare diseases, Cancer diseases, Blood diseases, Immune diseases

Aliases & Classifications for Hodgkin Lymphoma

About this section

Aliases & Descriptions for Hodgkin Lymphoma:

Name: Hodgkin Lymphoma 51 11 47 24 12 13 34
Hodgkin Disease 11 47 69 49 37 67
Hodgkin's Lymphoma 34 11 47 13
Lymphoma, Hodgkin's 47 26
Hodgkin's Disease of Lymph Nodes of Inguinal Region and/or Lower Limb 67
Hodgkin's Disease of Intrapelvic Lymph Nodes 67
Stage Ii Subdiaphragmatic Hodgkin Lymphoma 11
Stage I Subdiaphragmatic Hodgkin Lymphoma 11
 
Lymphoma, Hodgkin, Classic 69
Classic Hodgkin Lymphoma 53
Classic Hodgkin Disease 53
Hodgkins Lymphoma 11
Hodgkin's Sarcoma 11
Chl 69
Hl 11

Characteristics:

Orphanet epidemiological data:

53
classic hodgkin lymphoma:
Prevalence: 1-9/100000 (Europe),1-9/100000 (France),1-5/10000 (Europe),1-9/100000 (United States); Age of onset: All ages; Age of death: any age

HPO:

63
hodgkin lymphoma:
Inheritance: autosomal recessive inheritance

Classifications:



Summaries for Hodgkin Lymphoma

About this section
MedlinePlus:37 Hodgkin disease is a type of lymphoma. lymphoma is a cancer of a part of the immune system called the lymph system. the first sign of hodgkin disease is often an enlarged lymph node. the disease can spread to nearby lymph nodes. later it may spread to the lungs, liver, or bone marrow. the exact cause is unknown. hodgkin disease is rare. symptoms include painless swelling of the lymph nodes in the neck, armpits, or groin fever and chills night sweats weight loss loss of appetite itchy skin to diagnose hodgkin disease, doctors use a physical exam and history, blood tests, and a biopsy. treatment depends on how far the disease has spread. it often includes radiation therapy or chemotherapy. the earlier the disease is diagnosed, the more effective the treatment. in most cases, hodgkin disease can be cured. nih: national cancer institute

MalaCards based summary: Hodgkin Lymphoma, also known as hodgkin disease, is related to hemolytic anemia and hepatoblastoma, and has symptoms including lymphoma, lymphadenopathy and abnormality of immune system physiology. An important gene associated with Hodgkin Lymphoma is KLHDC8B (Kelch Domain Containing 8B), and among its related pathways are Estrogen signaling pathway and Direct p53 effectors. The drugs cisplatin and mechlorethamine hydrochloride have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related mouse phenotypes are endocrine/exocrine gland and hematopoietic system.

UniProtKB/Swiss-Prot:69 Lymphoma, Hodgkin, classic: A malignant disease characterized by progressive enlargement of the lymph nodes, spleen and general lymphoid tissue, and the presence of large, usually multinucleate, cells (Reed-Sternberg cells). Reed- Sternberg cells compose only 1-2% of the total tumor cell mass. The remainder is composed of a variety of reactive, mixed inflammatory cells consisting of lymphocytes, plasma cells, neutrophils, eosinophils and histiocytes.

OMIM:51 Classic Hodgkin lymphoma is a lymph node cancer of germinal center B-cell origin. Hodgkin lymphoma tumors consist of a... (236000) more...

Disease Ontology:11 A lymphoma that is marked by the presence of a type of cell called the Reed-Sternberg cell.

Wikipedia:70 Hodgkin\'s lymphoma (HL) is a type of lymphoma, which is generally believed to result from white blood... more...

Related Diseases for Hodgkin Lymphoma

About this section

Diseases related to Hodgkin Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 357)
idRelated DiseaseScoreTop Affiliating Genes
1hemolytic anemia30.3ALK, BCL6, CSF3, NPM1, PAX5, TNFRSF8
2hepatoblastoma29.6BCL6, CSF3, PAX5, REL, TNFRSF8
3lymphoma, non-hodgkin12.2
4nodular lymphocyte predominant hodgkin lymphoma12.2
5classic hodgkin lymphoma, mixed cellularity type12.0
6classic hodgkin lymphoma, lymphocyte-rich type12.0
7hodgkin lymphoma, during pregnancy12.0
8non-hodgkin lymphoma, during pregnancy12.0
9lymphoma12.0
10hodgkin lymphoma, childhood11.9
11non-hodgkin lymphoma, childhood11.9
12hodgkin's lymphoma, lymphocytic depletion11.5
13hodgkin's lymphoma, nodular sclerosis11.5
14hodgkin's lymphoma, lymphocytic-histiocytic predominance11.5
15anaplastic large cell lymphoma11.5
16hodgkin's lymphoma, mixed cellularity11.4
17b-cell lymphomas11.4
18hepatic lipase deficiency11.3
19follicular lymphoma11.3
20composite lymphoma11.2
21gray zone lymphoma11.2
22mediastinal gray zone lymphoma11.2
23lymphoma, malt, somatic11.2
24familial hodgkin disease11.0
25follicular lymphoma 111.0
26orbit lymphoma11.0
27primary oculocerebral lymphoma10.9
28lung cancer susceptibility 410.8BCL2, BCL6
29primary cutaneous unspecified peripheral t-cell lymphoma10.8BCL2, BCL6
30hydrolethalus syndrome10.8
31lipase deficiency, combined10.8
32hmg-coa lyase deficiency10.8
33acute motor axonal neuropathy10.7BCL2, BCL6
34radiation cystitis10.7BRAF, CSF3
35minimally differentiated acute myeloblastic leukemia10.7BCL6, REL
36eosinophilic granulomatosis with polyangiitis10.7ALK, FSCN1
37atrial standstill10.6ALK, BCL2, BRAF
38pityriasis rotunda10.6MS4A1, TNFRSF8
39diffuse large b-cell lymphoma with chronic inflammation10.6ALK, NPM1
40congenital sucrase-isomaltase deficiency with starch intolerance10.6ALK, NPM1
41steroid dehydrogenase deficiency dental anomalies10.6ALK, NPM1, TNFRSF8
42estrogen-receptor positive breast cancer10.6ALK, NPM1, TNFRSF8
43tinea cruris10.6ALK, CSF3, TNFRSF8
44endometrioid ovary carcinoma10.6ALK, CSF3, PRDM1
45polyembryoma of the ovary10.5BCL6, PAX5, TNFRSF8
46ischemic optic neuropathy10.5BCL2, PAX5
47hodgkin's granuloma10.5
48primary mediastinal large b-cell lymphoma10.5
49teebi kaurah syndrome10.4BCL6, TNFRSF8
50chronic myocardial ischemia10.4BCL2, BCL6, CSF3, MS4A1

Graphical network of the top 20 diseases related to Hodgkin Lymphoma:



Diseases related to hodgkin lymphoma

Symptoms for Hodgkin Lymphoma

About this section

Symptoms by clinical synopsis from OMIM:

236000

Clinical features from OMIM:

236000

Human phenotypes related to Hodgkin Lymphoma:

 63 (show all 23)
id Description HPO Frequency HPO Source Accession
1 lymphoma63 hallmark (90%) HP:0002665
2 lymphadenopathy63 hallmark (90%) HP:0002716
3 abnormality of immune system physiology63 hallmark (90%) HP:0010978
4 hyperhidrosis63 typical (50%) HP:0000975
5 pruritus63 typical (50%) HP:0000989
6 weight loss63 typical (50%) HP:0001824
7 anorexia63 typical (50%) HP:0002039
8 abnormality of temperature regulation63 typical (50%) HP:0004370
9 chest pain63 typical (50%) HP:0100749
10 skin rash63 occasional (7.5%) HP:0000988
11 splenomegaly63 occasional (7.5%) HP:0001744
12 migraine63 occasional (7.5%) HP:0002076
13 respiratory insufficiency63 occasional (7.5%) HP:0002093
14 hemoptysis63 occasional (7.5%) HP:0002105
15 hepatomegaly63 occasional (7.5%) HP:0002240
16 incoordination63 occasional (7.5%) HP:0002311
17 bone pain63 occasional (7.5%) HP:0002653
18 osteolysis63 occasional (7.5%) HP:0002797
19 bone marrow hypocellularity63 occasional (7.5%) HP:0005528
20 peripheral neuropathy63 occasional (7.5%) HP:0009830
21 impaired lymphocyte transformation with phytohemagglutinin63 HP:0003347
22 polyclonal elevation of igm63 HP:0003459
23 hodgkin lymphoma63 HP:0012189

Drugs & Therapeutics for Hodgkin Lymphoma

About this section

FDA approved drugs:

(show all 10)
id Drug Name Active Ingredient(s)16 Company Approval Date
1
Adcetris16 43 BRENTUXIMAB VEDOTIN Seattle Genetics August 2011
FDA Label: Adcetris
Disease/s that Drug Treats:Hodgkin lymphoma and anaplastic large cell lymphoma
Indications and Usage:16 ADCETRIS is a CD30-directed antibody-drug conjugate indicated fortreatment of patients with: Hodgkin lymphoma after failure of autologous stem cell transplant(ASCT) or after failure of at least two prior multi-agent chemotherapyregimens in patients who are not ASCT candidates (1.1). Systemic anaplastic large cell lymphoma after failure of at least oneprior multi-agent chemotherapy regimen (1.2).Accelerated approval was granted for the above indications based onoverall response rate. An improvement in patient-reported outcomes orsurvival has not been established. Continued approval for these indicationsmay be contingent upon verification and description of clinical benefit inconfirmatory trials.
DrugBank Targets:14 Tumor necrosis factor receptor superfamily member 8
Mechanism of Action:16 
Target: microtubule
Action: disruptor
FDA: Brentuximab vedotin is an ADC. The antibody is a chimeric IgG1 directed against CD30. Thesmall molecule, MMAE, is a microtubule disrupting agent. MMAE is covalently attached to theantibody via a linker. Nonclinical data suggest that the anticancer activity of ADCETRIS is dueto the binding of the ADC to CD30-expressing cells, followed by internalization of theADC-CD30 complex, and the release of MMAE via proteolytic cleavage. Binding of MMAE totubulin disrupts the microtubule network within the cell, subsequently inducing cell cycle arrestand apoptotic death of the cells.
2
Bexxar16 43 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa June 2003
FDA Label: Bexxar
Disease/s that Drug Treats:Non-Hodgkin's Lymphoma
Indications and Usage:16 BEXXAR (tositumomab and Iodine I 131 tositumomab) is a CD20-directedradiotherapeutic antibody indicated for the treatment of patients with CD20-positive, relapsed or refractory, low-grade, follicular, or transformed nonHodgkin'slymphoma who have progressed during or after rituximab therapy,including patients with rituximab-refractory non-Hodgkin's lymphoma. (1.1)Determination of the effectiveness of the BEXXAR therapeutic regimen isbased on overall response rates in patients whose disease is refractory tochemotherapy and rituximab. The effects of the BEXXAR therapeuticregimen on survival are not known. (1.1)Important Limitation of Use BEXXAR therapeutic regimen is only indicated for a single course oftreatment and is not indicated for a first-line treatment. (1.2)
DrugBank Targets:14 1. B-lymphocyte antigen CD20;2. Low affinity immunoglobulin gamma Fc region receptor III-B;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Low affinity immunoglobulin gamma Fc region receptor III-A;8. High affinity immunoglobulin gamma Fc receptor I;9. Low affinity immunoglobulin gamma Fc region receptor II-a;10.Low affinity immunoglobulin gamma Fc region receptor II-b;11. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:16 
Target: CD20
Action: cytotoxic antibody
FDA: Tositumomab binds specifically to an epitope within the extracellular domain of the586 CD20 molecule. The CD20 molecule is expressed on normal B lymphocytes (pre-B lymphocytes587 to mature B lymphocytes) and on B-cell non-Hodgkin's lymphomas. The CD20 molecule is not588 shed from the cell surface and is not internalized following antibody binding. The BEXXAR589 therapeutic regimen induces cell death by emitting ionizing radiation to CD20-expressing590 lymphocytes or neighboring cells. In addition to cell death mediated by the radioisotope, other591 possible mechanisms of action include antibody-dependent cellular cytotoxicity, complement-592 dependent cytotoxicity, and CD20-mediated apoptosis.
3
Gardasil16 43 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006
FDA Label: Gardasil
Disease/s that Drug Treats:Cervical Cancer Caused by Human Papillomavirus
Indications and Usage:16 GARDASIL is a vaccine indicated in girls and women 9 through 26years of age for the prevention of the following diseases caused byHuman Papillomavirus (HPV) types included in the vaccine: Cervical, vulvar, vaginal, and anal cancer caused by HPV types 16and 18 (1.1) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.1)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Cervical intraepithelial neoplasia (CIN) grade 2/3 and Cervicaladenocarcinoma in situ (AIS) (1.1) Cervical intraepithelial neoplasia (CIN) grade 1 (1.1) Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3 (1.1) Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3 (1.1) Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3 (1.1)GARDASIL is indicated in boys and men 9 through 26 years of age forthe prevention of the following diseases caused by HPV types includedin the vaccine: Anal cancer caused by HPV types 16 and 18 (1.2) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.2)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3. (1.2)Limitations of GARDASIL Use and Effectiveness: GARDASIL does not eliminate the necessity for women tocontinue to undergo recommended cervical cancer screening.(1.3, 17) Recipients of GARDASIL should not discontinue anal cancerscreening if it has been recommended by a health care provider.(1.3, 17) GARDASIL has not been demonstrated to provide protectionagainst disease from vaccine and non-vaccine HPV types to whicha person has previously been exposed through sexual activity.(1.3, 14.4, 14.5) GARDASIL is not intended to be used for treatment of activeexternal genital lesions; cervical, vulvar, vaginal, and analcancers; CIN; VIN; VaIN, or AIN. (1.3) GARDASIL has not been demonstrated to protect againstdiseases due to HPV types not contained in the vaccine. (1.3,14.4, 14.5) Not all vulvar, vaginal, and anal cancers are caused by HPV, andGARDASIL protects only against those vulvar, vaginal, and analcancers caused by HPV 16 and 18. (1.3) GARDASIL does not protect against genital diseases not causedby HPV. (1.3) Vaccination with GARDASIL may not result in protection in allvaccine recipients. (1.3) GARDASIL has not been demonstrated to prevent HPV-relatedCIN 2/3 or worse in women older than 26 years of age. (14.7)
DrugBank Targets: -
Mechanism of Action:16 
Target: humoral immune response
Action: inducer
FDA: HPV only infects human beings. Animal studies with analogous animal papillomaviruses suggest thatthe efficacy of L1 VLP vaccines may involve the development of humoral immune responses. Humanbeings develop a humoral immune response to the vaccine, although the exact mechanism of protectionis unknown.
4
Intron A16 43 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
FDA Label: Intron A
Disease/s that Drug Treats:non-Hodgkin's lymphoma/ malignant melanoma / Hepatitis C
Indications and Usage:16 Hairy Cell Leukemia INTRON® A is indicated for the treatment of patients 18 years ofage or older with hairy cell leukemia.Malignant Melanoma INTRON A is indicated as adjuvant to surgical treatment inpatients 18 years of age or older with malignant melanoma who are free of disease butat high risk for systemic recurrence, within 56 days of surgery.Follicular Lymphoma INTRON A is indicated for the initial treatment of clinicallyaggressive (see Clinical Pharmacology) follicular Non-Hodgkin’s Lymphoma inconjunction with anthracycline-containing combination chemotherapy in patients 18years of age or older. Efficacy of INTRON A therapy in patients with low-grade, lowtumorburden follicular Non-Hodgkin’s Lymphoma has not been demonstrated.Condylomata Acuminata INTRON A is indicated for intralesional treatment of selectedpatients 18 years of age or older with condylomata acuminata involving externalsurfaces of the genital and perianal areas (see DOSAGE AND ADMINISTRATION).The use of this product in adolescents has not been studied.AIDS-Related Kaposi's Sarcoma INTRON A is indicated for the treatment of selectedpatients 18 years of age or older with AIDS-Related Kaposi's Sarcoma. The likelihoodof response to INTRON A therapy is greater in patients who are without systemic symptoms, who have limited lymphadenopathy and who have a relatively intact immunesystem as indicated by total CD4 count.Chronic Hepatitis C INTRON A is indicated for the treatment of chronic hepatitis C inpatients 18 years of age or older with compensated liver disease who have a history ofblood or blood-product exposure and/or are HCV antibody positive. Studies in thesepatients demonstrated that INTRON A therapy can produce clinically meaningful effectson this disease, manifested by normalization of serum alanine aminotransferase (ALT)and reduction in liver necrosis and degeneration.A liver biopsy should be performed to establish the diagnosis of chronic hepatitis.Patients should be tested for the presence of antibody to HCV. Patients with othercauses of chronic hepatitis, including autoimmune hepatitis, should be excluded. Priorto initiation of INTRON A therapy, the physician should establish that the patient hascompensated liver disease. The following patient entrance criteria for compensated liverdisease were used in the clinical studies and should be considered before INTRON Atreatment of patients with chronic hepatitis C: No history of hepatic encephalopathy, variceal bleeding, ascites, or otherclinical signs of decompensation Bilirubin Less than or equal to 2 mg/dL Albumin Stable and within normal limits Prothrombin Time Less than 3 seconds prolonged WBC Greater than or equal to 3000/mm3 Platelets Greater than or equal to 70,000/mm3Serum creatinine should be normal or near normal.Prior to initiation of INTRON A therapy, CBC and platelet counts should beevaluated in order to establish baselines for monitoring potential toxicity. These testsshould be repeated at Weeks 1 and 2 following initiation of INTRON A therapy, andmonthly thereafter. Serum ALT should be evaluated at approximately 3-month intervalsto assess response to treatment (see DOSAGE AND ADMINISTRATION).Patients with preexisting thyroid abnormalities may be treated if thyroidstimulatinghormone (TSH) levels can be maintained in the normal range by medication.TSH levels must be within normal limits upon initiation of INTRON A treatment and TSHtesting should be repeated at 3 and 6 months (see PRECAUTIONS, LaboratoryTests).INTRON A in combination with REBETOL® is indicated for the treatment ofchronic hepatitis C in patients 3 years of age and older with compensated liver diseasepreviously untreated with alpha interferon therapy and in patients 18 years of age andolder who have relapsed following alpha interferon therapy. See REBETOL prescribinginformation for additional information. Chronic Hepatitis B INTRON A is indicated for the treatment of chronic hepatitis B inpatients 1 year of age or older with compensated liver disease. Patients who have beenserum HBsAg positive for at least 6 months and have evidence of HBV replication(serum HBeAg positive) with elevated serum ALT are candidates for treatment. Studiesin these patients demonstrated that INTRON A therapy can produce virologic remissionof this disease (loss of serum HBeAg) and normalization of serum aminotransferases.INTRON A therapy resulted in the loss of serum HBsAg in some responding patients.Prior to initiation of INTRON A therapy, it is recommended that a liver biopsy beperformed to establish the presence of chronic hepatitis and the extent of liver damage.The physician should establish that the patient has compensated liver disease. Thefollowing patient entrance criteria for compensated liver disease were used in theclinical studies and should be considered before INTRON A treatment of patients withchronic hepatitis B: No history of hepatic encephalopathy, variceal bleeding, ascites, or othersigns of clinical decompensation Bilirubin Normal Albumin Stable and within normal limits Prothrombin Time Adults less than 3 seconds prolongedPediatrics less than or equal to 2 seconds prolonged WBC Greater than or equal to 4000/mm3 Platelets Adults greater than or equal to 100,000/mm3Pediatrics greater than or equal to 150,000/mm3Patients with causes of chronic hepatitis other than chronic hepatitis B or chronichepatitis C should not be treated with INTRON A. CBC and platelet counts should beevaluated prior to initiation of INTRON A therapy in order to establish baselines formonitoring potential toxicity. These tests should be repeated at treatment Weeks 1, 2,4, 8, 12, and 16. Liver function tests, including serum ALT, albumin, and bilirubin,should be evaluated at treatment Weeks 1, 2, 4, 8, 12, and 16. HBeAg, HBsAg, andALT should be evaluated at the end of therapy, as well as 3- and 6-months posttherapy,since patients may become virologic responders during the 6-month periodfollowing the end of treatment. In clinical studies in adults, 39% (15/38) of respondingpatients lost HBeAg 1 to 6 months following the end of INTRON A therapy. Ofresponding patients who lost HBsAg, 58% (7/12) did so 1 to 6 months post-treatment.A transient increase in ALT greater than or equal to 2 times baseline value (flare)can occur during INTRON A therapy for chronic hepatitis B. In clinical trials in adultsand pediatrics, this flare generally occurred 8 to 12 weeks after initiation of therapy andwas more frequent in responders (adults 63%, 24/38; pediatrics 59%, 10/17) than innonresponders (adults 27%, 13/48; pediatrics 35%, 19/55). However, in adults andpediatrics, elevations in bilirubin greater than or equal to 3 mg/dL (greater than or equalto 2 times ULN) occurred infrequently (adults 2%, 2/86; pediatrics 3%, 2/72) duringtherapy. When ALT flare occurs, in general, INTRON A therapy should be continued unless signs and symptoms of liver failure are observed. During ALT flare, clinicalsymptomatology and liver function tests including ALT, prothrombin time, alkalinephosphatase, albumin, and bilirubin, should be monitored at approximately 2-weekintervals (see WARNINGS).
DrugBank Targets:14 1. Interferon alpha/beta receptor 2;2. Interferon alpha/beta receptor 1
Mechanism of Action:16 
Target: intracellular oncogene expression, natural killer and cytotoxic T-cells, microphage, cytokine production
Action: stimulation, induction (unspecified effects on oncogene expression)
FDA: -
5
Mozobil16 43 PLERIXAFOR Genzyme December 2008
FDA Label: Mozobil
Disease/s that Drug Treats:non-Hodgkin’s lymphoma and multiple myeloma
Indications and Usage:16 Mozobil, a hematopoietic stem cell mobilizer, is indicated in combinationwith granulocyte-colony stimulating factor (G-CSF) to mobilizehematopoietic stem cells (HSCs) to the peripheral blood for collection andsubsequent autologous transplantation in patients with non-Hodgkin’slymphoma and multiple myeloma. (1)
DrugBank Targets:14 1. C-X-C chemokine receptor type 4
Mechanism of Action:16 
Target: hematopoietic stem cell/ CXCR4 chemokine receptor
Action: monilizer/ inhibitor
FDA: Plerixafor is an inhibitor of the CXCR4 chemokine receptor and blocks binding of its cognateligand, stromal cell-derived factor-1α (SDF-1α). SDF-1α and CXCR4 are recognized to play arole in the trafficking and homing of human hematopoietic stem cells (HSCs) to the marrowcompartment. Once in the marrow, stem cell CXCR4 can act to help anchor these cells to themarrow matrix, either directly via SDF-1α or through the induction of other adhesion molecules.Treatment with plerixafor resulted in leukocytosis and elevations in circulating hematopoieticprogenitor cells in mice, dogs and humans. CD34+ cells mobilized by plerixafor were capable ofengraftment with long-term repopulating capacity up to one year in canine transplantationmodels.
6
Rituxan16 43 RITUXIMAB Biogen IDEC, Genentech November 1997
FDA Label: Rituxan
Disease/s that Drug Treats:non-hodgkin's lymphoma
Indications and Usage:16 Rituxan® (rituximab) is a CD20-directed cytolytic antibody indicated for thetreatment of patients with: Non-Hodgkin’s Lymphoma (NHL) (1.1) Chronic Lymphocytic Leukemia (CLL) (1.2) Rheumatoid Arthritis (RA) in combination with methotrexate in adultpatients with moderately-to severely-active RA who have inadequateresponse to one or more TNF antagonist therapies (1.3) Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) andMicroscopic Polyangiitis (MPA) in adult patients in combination withglucocorticoids (1.4)Limitations of Use: Rituxan is not recommended for use in patients withsevere, active infections (1.5).
DrugBank Targets:14 1. Low affinity immunoglobulin gamma Fc region receptor III-B;2. Complement C1r subcomponent;3. Complement C1q subcomponent subunit A;4. Complement C1q subcomponent subunit B;5. Complement C1q subcomponent subunit C;6. Low affinity immunoglobulin gamma Fc region receptor III-A;7. Complement C1s subcomponent;8. High affinity immunoglobulin gamma Fc receptor I;9. Low affinity immunoglobulin gamma Fc region receptor II-a;10. Low affinity immunoglobulin gamma Fc region receptor II-b;11. Low affinity immunoglobulin gamma Fc region receptor II-c;12. B-lymphocyte antigen CD20
Mechanism of Action:16 
Target: CD20 antigen expressed on the surface ofpre-B and mature B-lymphocytes
Action: mediator of B-cell lysis through different possible types of cytotoxicity
FDA: Rituximab is a monoclonal antibody that targets the CD20 antigen expressed on the surface ofpre-B and mature B-lymphocytes. Upon binding to CD20, rituximab mediates B-cell lysis. Possiblemechanisms of cell lysis include complement dependent cytotoxicity (CDC) and antibody dependentcell mediated cytotoxicity (ADCC). The antibody induced apoptosis in the DHL 4 human B celllymphoma cell line.B cells are believed to play a role in the pathogenesis of rheumatoid arthritis (RA) and associatedchronic synovitis. In this setting, B cells may be acting at multiple sites in theautoimmune/inflammatory process, including through production of rheumatoid factor (RF) andother autoantibodies, antigen presentation, T-cell activation, and/or proinflammatory cytokineproduction.
7
Sutent16 43 SUNITINIB MALATE Pfizer May 2011/ January 2006
FDA Label: Sutent
Disease/s that Drug Treats:pancreatic neuroendocrine tumors/ Kidney Cancer/Gastrointestinal Stromal Tumors
Indications and Usage:16 SUTENT is a kinase inhibitor indicated for the treatment of: Gastrointestinal stromal tumor (GIST) after disease progression on orintolerance to imatinib mesylate. (1.1) Advanced renal cell carcinoma (RCC). (1.2) Progressive, well-differentiated pancreatic neuroendocrine tumors(pNET) in patients with unresectable locally advanced or metastaticdisease. (1.3)
DrugBank Targets:14 1. Platelet-derived growth factor receptor beta;2. Vascular endothelial growth factor receptor 1;3. Mast/stem cell growth factor receptor Kit;4. Vascular endothelial growth factor receptor 2;5. Vascular endothelial growth factor receptor 3;6. Receptor-type tyrosine-protein kinase FLT3;7. Macrophage colony-stimulating factor 1 receptor;8. Platelet-derived growth factor receptor alpha
Mechanism of Action:16 
Target: variety of kinases, platelet-derived growth factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factorreceptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3(FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factorreceptor (RET)
Action: inhibitor
FDA: Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which areimplicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib wasevaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitorof platelet-derived growth factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factorreceptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3(FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factorreceptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical andcellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primarymetabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays.Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFR, VEGFR2, KIT) in tumor xenograftsexpressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/orinhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibitgrowth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibitPDGFR- and VEGFR2-dependent tumor angiogenesis in vivo.
8
Treanda16 43 BENDAMUSTINE HYDROCHLORIDE Cephalon October 2008
FDA Label: Treanda
Disease/s that Drug Treats:Chronic lymphocytic leukemia and B-cell non-Hodgkin’s lymphoma
Indications and Usage:16 TREANDA is an alkylating drug indicated for treatment of patients with: Chronic lymphocytic leukemia (CLL). Efficacy relative to first linetherapies other than chlorambucil has not been established. (1.1) Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed duringor within six months of treatment with rituximab or a rituximab-containingregimen. (1.2)
DrugBank Targets: -
Mechanism of Action:16 
Target: -
Action: -
FDA: Bendamustine is a bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring.Mechlorethamine and its derivatives form electrophilic alkyl groups. These groups form covalent bonds with electronrichnucleophilic moieties, resulting in interstrand DNA crosslinks. The bifunctional covalent linkage can lead to celldeath via several pathways. Bendamustine is active against both quiescent and dividing cells. The exact mechanism ofaction of bendamustine remains unknown.
9
Zevalin16 43 IBRITUMOMAB TIUXETAN Biogen IDEC February 2002
FDA Label: Zevalin
Disease/s that Drug Treats:Non-Hodgkin's lymphoma
Indications and Usage:16 Zevalin is a CD20-directed radiotherapeutic antibody administered as part ofthe Zevalin therapeutic regimen indicated for the treatment of patients with: relapsed or refractory, low-grade or follicular B-cell non-Hodgkin'slymphoma (NHL) (1.1). previously untreated follicular NHL who achieve a partial or completeresponse to first-line chemotherapy (1.2).
DrugBank Targets:14 1. B-lymphocyte antigen CD20;2. Low affinity immunoglobulin gamma Fc region receptor III-B;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Low affinity immunoglobulin gamma Fc region receptor III-A;8. Complement C1s subcomponent;9. High affinity immunoglobulin gamma Fc receptor I;10. Low affinity immunoglobulin gamma Fc region receptor II-a;11. Low affinity immunoglobulin gamma Fc region receptor II-b;12. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:16 
Target: CD20 antigen --> Y-90
Action: beta emission causes damage
FDA: Ibritumomab tiuxetan binds specifically to the CD20 antigen (human B-lymphocyte-restricted differentiation antigen,Bp35). The apparent affinity (KD) of ibritumomab tiuxetan for the CD20 antigen ranges between approximately 14 to18 nM. The CD20 antigen is expressed on pre-B and mature B lymphocytes and on > 90% of B-cell non-Hodgkin’slymphomas (NHL). The CD20 antigen is not shed from the cell surface and does not internalize upon antibody binding.The chelate tiuxetan, which tightly binds Y-90, is covalently linked to ibritumomab. The beta emission from Y-90induces cellular damage by the formation of free radicals in the target and neighboring cells.Ibritumomab tiuxetan binding was observed in vitro on lymphoid cells of the bone marrow, lymph node, thymus, red andwhite pulp of the spleen, and lymphoid follicles of the tonsil, as well as lymphoid nodules of other organs such as thelarge and small intestines.
Y-90
Action: beta emission causes damage
Medilexicon: The complementarity-determining regions of Ibritumomab bind to the CD20 antigen on B lymphocytes. Ibritumomab, like Rituximab, induces apoptosis in CD20+ B-cell lines in vitro. The chelate tiuxetan, which tightly binds In-111 or Y-90, is covalently linked to the amino groups of exposed lysines and arginines contained within the antibody. The beta emission from Y-90 induces cellular damage by the formation of free radicals in the target and neighboring cells. (from Zevalin Prescribing Information)
FDA: Ibritumomab tiuxetan binds specifically to the CD20 antigen (human B-lymphocyte-restricted differentiation antigen,Bp35). The apparent affinity (KD) of ibritumomab tiuxetan for the CD20 antigen ranges between approximately 14 to18 nM. The CD20 antigen is expressed on pre-B and mature B lymphocytes and on > 90% of B-cell non-Hodgkin’slymphomas (NHL). The CD20 antigen is not shed from the cell surface and does not internalize upon antibody binding.The chelate tiuxetan, which tightly binds Y-90, is covalently linked to ibritumomab. The beta emission from Y-90induces cellular damage by the formation of free radicals in the target and neighboring cells.Ibritumomab tiuxetan binding was observed in vitro on lymphoid cells of the bone marrow, lymph node, thymus, red andwhite pulp of the spleen, and lymphoid follicles of the tonsil, as well as lymphoid nodules of other organs such as thelarge and small intestines.
Drug info:
-->
10
Zydelig16 43 IDELALISIB Gilead July 2014
FDA Label: Zydelig
Disease/s that Drug Treats:relapsed CLL, follicular B-cell NHL and small lymphocytic lymphoma
Indications and Usage:16 Zydelig is a kinase inhibitor indicated for the treatment of patients with: Relapsed chronic lymphocytic leukemia (CLL), in combination withrituximab, in patients for whom rituximab alone would be consideredappropriate therapy due to other co-morbidities. (1.1) Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patientswho have received at least two prior systemic therapies. (1.2) Relapsed small lymphocytic lymphoma (SLL) in patients who havereceived at least two prior systemic therapies. (1.3)Accelerated approval was granted for FL and SLL based on overallresponse rate. Improvement in patient survival or disease relatedsymptoms has not been established. Continued approval for theseindications may be contingent upon verification of clinical benefit inconfirmatory trials.
DrugBank Targets:14 1. Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta isoform (P110δ)
Mechanism of Action:16 
Target: PI3Kδ kinase
Action: inhibitor
FDA: Idelalisib is an inhibitor of PI3Kδ kinase, which is expressed in normal and malignant Bcells.Idelalisib induced apoptosis and inhibited proliferation in cell lines derived frommalignant B-cells and in primary tumor cells. Idelalisib inhibits several cell signalingpathways, including B-cell receptor (BCR) signaling and the CXCR4 and CXCR5signaling, which are involved in trafficking and homing of B-cells to the lymph nodes andbone marrow. Treatment of lymphoma cells with idelalisib resulted in inhibition ofchemotaxis and adhesion, and reduced cell viability.

Drugs for Hodgkin Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 572)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Dacarbazineapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 16744342-03-45351166
Synonyms:
(5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
(5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
(Dimethyltriazeno)imidazolecarboxamide
37626-23-6
4(5)-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide
4(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide
4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide
4-(3,3-Dimethyltriazeno)imidazole-5-carboxamide
4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide
4-(Dimethyltriazeno)imidazole-5-c arboxamide
4-(Dimethyltriazeno)imidazole-5-carboxamide
4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide
4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide
4-[(1E)-3,3-Dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide
4-[3,3-dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide
4342-03-4
5(or 4)-(dimethyltriazeno)imidazol e-4(or 5)-carboxamide
5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide
5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide
5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide
5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide
5-(3,3-Dimethyltri azeno)imidazole-4-carboxamide
5-(3,3-Dimethyltriazeno)-imidazole-4-carbamide
5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide
5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide
5-(Dimethyltriazeno)-4-imidazolecarboxamide
5-(Dimethyltriazeno)imidazole-4-carboxamide
5-(Dimethyltriazeno)imidazole-4-carboximide
5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide
94361-71-4
AC1NQXVV
AC1NS01W
AC1NS4BN
AI3-52825
BPBio1_000428
BRD-K35520305-001-07-8
BSPBio_000388
BSPBio_002091
Biocarbazin
Biocarbazine
Biocarbazine R
C6H10N6O
CAS-891986
CCRIS 190
CHEBI:4305
CHEMBL476
CID5281007
CID5351166
CID5353562
Carboxamide, Dimethyl Imidazole
D00288
D003606
D2390_SIGMA
D3634
DB00851
DIC
DTCI
DTIC
DTIC Dome
DTIC, DTIC-Dome, Dacarbazine
DTIC-Dome
DTICDome
DTIE
Dacarbazin
Dacarbazina
Dacarbazine
Dacarbazine (JAN/USP/INN)
Dacarbazine [USAN:INN:BAN:JAN]
Dacarbazino
Dacarbazino [INN-Spanish]
Dacarbazinum
Dacarbazinum [INN-Latin]
 
Dacatic
Decarbazine
Deticene
Di-me-triazenoimidazolecarboxamide
Di-methyl-triazenoimidazolecarboxamide
Dimethyl Imidazole Carboxamide
Dimethyl Triazeno Imidazole Carboxamide
Dimethyltriazenoimidazolecarboxamide
DivK1c_000326
Dtic-Dome
Dtic-Dome (TN)
Dtic-dome (tn)
EINECS 224-396-1
HE1150000
HMS1569D10
HMS2090A20
HMS2091I20
HMS501A08
HSDB 3219
I06-2280
I14-1659
ICDMT
ICDT
IDI1_000326
Imidazole Carboxamide
Imidazole Carboxamide, Dimethyl
Imidazole carboxamide
KBio1_000326
KBio2_001364
KBio2_003932
KBio2_006500
KBio3_001311
KBioGR_000896
KBioSS_001364
LS-119
MLS001332543
MLS001332544
MolPort-003-666-153
MolPort-003-846-120
MolPort-006-709-420
NCGC00016986-01
NCGC00091861-01
NCGC00091861-02
NCGC00091861-03
NCGC00091861-04
NCI-C04717
NCI60_004053
NCIMech_000261
NINDS_000326
NIOSH/HE1150000
NPFAPI-05
NSC 45388
NSC-45388
NSC45388
Prestwick0_000574
Prestwick1_000574
Prestwick2_000574
Prestwick3_000574
Prestwick_904
S1221_Selleck
SMP2_000251
SMR000857131
SPBio_001075
SPBio_002607
SPECTRUM1500218
ST51014976
Spectrum2_001148
Spectrum3_000366
Spectrum4_000308
Spectrum5_000823
Spectrum_000884
UNII-7GR28W0FJI
WLN: T5M CNJ DVZ ENUNN1&1
dacarbazine
2
EpirubicinapprovedPhase 4, Phase 3, Phase 238356420-45-241867
Synonyms:
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione
4'-Epi-DXR
4'-Epiadriamycin
4'-Epidoxorubicin
4'-epi-DX
4'-epi-Doxorubicin
4'-epidoxorubicin
4-Epidoxorubicin
56390-09-1
56390-09-1 (hydrochloride)
56420-45-2
57918-25-9
AC1L26NP
AC1Q6JIV
BRN 1445813
C11230
C27H29NO11
CCRIS 2261
CHEBI:47898
CHEMBL417
CID41867
D07901
DB00445
Ellence
Epi-DX
Epi-Dx
Epiadriamycin
Epidoxorubicin
Epirubicin
 
Epirubicin (INN)
Epirubicin [INN:BAN]
Epirubicina
Epirubicina [INN-Spanish]
Epirubicina [Spanish]
Epirubicine
Epirubicine [French]
Epirubicine [INN-French]
Epirubicinum
Epirubicinum [INN-Latin]
Epirubicinum [Latin]
Farmorubicin (TN)
HSDB 6962
IMI 28
LS-187190
LS-93992
MLS000759412
NChemBio.2007.10-comp15
NSC 256942
NSC-256942
NSC256942
Pharmorubicin Pfs
Pidorubicin
Pidorubicina
Pidorubicina [INN-Spanish]
Pidorubicine
Pidorubicine [INN-French]
Pidorubicinum
Pidorubicinum [INN-Latin]
Ridorubicin
SMR000466308
Triferric doxorubicin
UNII-3Z8479ZZ5X
WP 697
3
EtoposideapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1123233419-42-036462
Synonyms:
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
Ambap33419-42-0
BPBio1_000673
BRD-K37798499-001-02-5
BSPBio_000611
Bio1_000489
Bio1_000978
Bio1_001467
C01576
CCRIS 2392
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
EPE
EPEG
ETOP
Epipodophyllotoxin
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
 
Eposin, Vepesid, VP-16, Toposar, Etoposide
Etopol
Etopophos
Etopophos (phosphate salt)
Etoposid
Etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide [USAN:INN:BAN:JAN]
Etoposido
Etoposido [INN-Spanish]
Etoposidum
Etoposidum [INN-Latin]
Etosid
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
LS-1214
Lastet
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
NK 171
NSC 141540
NSC-141540
NSC141540
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Prestwick_211
S1225_Selleck
SAM001246880
SMR000112002
SPBio_002532
ST056353
Toposar
UNII-6PLQ3CP4P3
VP 16
VP 16 (pharmaceutical)
VP 16-213
VP 16213
VP-16
VP-16-213
VePESID (TN)
VePesid
Vepesid
Vepesid J
Vepeside
ZINC03830818
ZINC03938684
Zuyeyidal
etoposide
nchembio.573-comp8
nchembio873-comp2
trans-Etoposide
4
BleomycinapprovedPhase 4, Phase 3, Phase 2, Phase 115311056-06-75360373
Synonyms:
(betaR)-N(alpha)-{[6-amino-2-((1S)-3-amino-1-{[(2S)-2,3-diamino-3-oxopropyl]amino}-3-oxopropyl)-5-methylpyrimidin-4-yl]carbonyl}-beta-{2-O-[3-O-(aminocarbonyl)-alpha-D-mannopyranosyl]-alpha-L-gulopyranosyloxy}-N-[(1R,2S,3S)-5-({(1S,2R)-1-[({2-[4-({[3-(dimethylsulfonio)propyl]amino}carbonyl)-2,4'-bi-1,3-thiazol-2'-yl]ethyl}amino)carbonyl]-2-hydroxypropyl}amino)-3-hydroxy-4-methyl-5-oxopentan-2-yl]-L-histidinamide
11056-06-7
11116-31-7
1400-95-9
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[3-[4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
37208-04-1
37293-16-6
37353-43-8
9041-93-4
9041-93-4 (sulfate (salt))
AC1L9UFF
AC1NSEJD
AC1NUTOQ
BLM
Blenoxane
Bleo
Bleocin
Bleogin
Bleomicin
Bleomicina
Bleomicina [INN-Spanish]
Bleomycin A(2)
Bleomycin A2
Bleomycin A2 & Bleomycin B2.
Bleomycin B(2)
Bleomycin B2
Bleomycin sulfate
Bleomycin sulphate
 
Bleomycine
Bleomycine [INN-French]
Bleomycins
Bleomycinum
Bleomycinum [INN-Latin]
C06854
C55H85N17O21S3
C55H86N17O21S3
CCRIS 2754
CHEBI:3139
CHEMBL403664
CID456190
CID5360373
CID5460769
DB00290
EINECS 234-356-5
HSDB 3208
LMPK14000006
LS-44860
LS-524
N(1)-[3-(dimethylsulfonio)propyl]bleomycinamide
N1-(3-(Dimethylsulfonio)propyl)bleomycinamide
NDC 0015-3010
NSC 125066
Pingyangmyvin A2
STOCK1N-74760
UNII-13M89UEA7W
UNII-40S1VHN69B
Zhengguangmycin A2
Zhengguangmycin A2 [Chinese]
bleomycin
bleomycin a2
5
VinblastineapprovedPhase 4, Phase 3, Phase 2, Phase 1413865-21-413342, 241903
Synonyms:
(2ALPHA,2'BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE
(2alpha,2'BETA,3beta,4alpha,5beta)-vincaleukoblastine
(2xi,3beta,4'beta,19xi)-vincaleukoblastine
(3aR-(3aalpha,4beta,5beta,5abeta,9(3R*,5S*,7R*,9S*),10bR*,13aalpha))-methyl 4-(acetyloxy)-3a-ethyl-9-(5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-9-(methoxycarbonyl)-2H-3,7-methanoazacycloundecino(5,4-b)indol-9-yl)-3a,4,5,5a,6,11,12,13a-octahydro-5-hydroxy-8-methoxy-6-methyl-1H-indolizino(8,1-cd)carbazole-5-carboxylate
143-67-9
1z2b
29060-LE
865-21-4
AC-20335
AC1L21JC
AC1L68D2
AC1MXZJ2
BIDD:PXR0201
BRD-K01188359-065-02-5
BSPBio_001228
BSPBio_003594
Bio-0111
C07201
C46H58N4O9
CCRIS 9002
CHEBI:171516
CHEBI:27375
CHEMBL159
CHEMBL607706
CID13342
CID241903
CID3823887
CID6710780
D08675
DB00570
EINECS 212-734-0
HMS2090K05
HSDB 3263
KBio3_003033
LS-1859
LS-187263
 
MolPort-002-518-262
MolPort-005-910-359
NCGC00022585-04
NCGC00181127-01
NCI-C04842
NCI60_004200
NChemBio.2007.10-comp22
NDC 0002-1452-01
NSC 47842
Neuro_000020
Nincaluicolflastine
Rozevin
SPBio_000680
STOCK1N-38480
Spectrum2_000890
Spectrum3_001994
UNII-5V9KLZ54CY
VLB
VR-8
Velban
Velbe
Vinblastin
Vinblastina
Vinblastina (TN)
Vinblastina [DCIT]
Vinblastina [Dcit]
Vinblastine
Vinblastine (INN)
Vinblastine Sulfate
Vinblastine [INN:BAN]
Vinblastinum
Vinblastinum [INN-Latin]
Vincaleucoblastin
Vincaleucoblastine
Vincaleukoblastine
Vincoblastine
nchembio873-comp22
vinblastine
6
Methylprednisoloneapproved, vet_approvedPhase 4, Phase 3, Phase 2, Phase 1115383-43-26741
Synonyms:
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6alpha-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6-Methylprednisolone
6-alpha-Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
AC1L1N7A
Artisone-Wyeth
Artisone-wyeth
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
Besonia
Bio-0658
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
Depo-Medrol (acetate)
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
LMST02030178
LS-118498
Lemod
M0639_SIGMA
M1665
MEPRDL
MLS000028541
MLS001148159
MLS002207191
Medesone
Medixon
Medlone 21
 
Medrate
Medrol
Medrol (TN)
Medrol Adt Pak
Medrol Dosepak
Medrol adt pak
Medrol dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [DCIT]
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
NSC-19987
NSC19987
Nirypan
Noretona
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Prestwick_622
Promacortine
Reactenol
S1733_Selleck
SAM002589984
SMR000058330
SPBio_002377
Sieropresol
Solomet
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
delta(1)-6alpha-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
methylprednisolone
methylprenisolone
7
Prednisoloneapproved, vet_approvedPhase 4, Phase 3, Phase 2, Phase 1115350-24-85755
Synonyms:
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bio-0666
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
CO-Hydeltra
CPD000718761
Co-Hydeltra
Codelcortone
Cordrol
Cortalone
Cotogesic
Cotolone
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
Delta(1)-dehydrohydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Delta-Ef-Cortelan
Delta-Stab
Delta-stab
Deltacortenol
Deltacortril
Deltacortril Enteric
Deltahydrocortisone
Deltasolone
Deltisilone
Depo-Medrol
Derpo PD
Derpo Pd
Dexa-Cortidelt Hostacortin H
Dexa-Cortidelt hostacortin H
Di Adreson F
Di-Adreson F
Di-Adreson-F
Di-adreson F
DiAdresonF
Dicortol
Donisolone
Dydeltrone
EINECS 200-021-7
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
HMS1568H10
HMS2090J05
HSDB 3385
Hostacortin H
Hydeltra
Hydeltra-Tba
Hydeltrasol
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
I-Pred
Inflamase Forte
Inflamase Mild
K 1557
Key-Pred
Klismacort
LMST02030179
LS-7669
Lentosone
Lite Pred
M-Predrol
 
MLS001304083
MLS002154250
MLS002207037
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone Acetate
Meti-Derm
Meticortelone
Metreton
MolPort-002-507-147
NCGC00179649-01
NSC 9120
NSC9120
NSC9900
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
PRDL
PRED-G
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Predni-Dome
Prednicen
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone (JP15/USP/INN)
Prednisolone (anhydrous)
Prednisolone Acetate
Prednisolone Sodium Phosphate
Prednisolone Tebutate
Prednisolone [INN:BAN:JAN]
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Prestwick_404
Rolisone
S1737_Selleck
SAM002264639
SMR000718761
SPBio_002367
Scherisolon
Solone
Steran
Sterane
Sterolone
Supercortisol
UNII-9PHQ9Y1OLM
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
Ultracortene-hydrogen
ZINC03833821
component of Ataraxoid
component of K-Predne-Dome
delta(1)-Cortisol
delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
prednisolone
8
Prednisoneapproved, vet_approvedPhase 4, Phase 3, Phase 2, Phase 1135953-03-25865
Synonyms:
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
(8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione
.delta. E
.delta.(sup1)-Cortisone
.delta.-Cortelan
.delta.-Cortisone
.delta.-Cortone
.delta.-E
.delta.1-Cortisone
.delta.1-Dehydrocortisone
.delta.sone
1,2-Dehydrocortisone
1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1-Cortisone
1-Dehydrocortisone
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
53-03-2
68-59-7
81552_FLUKA
AC-11112
AC1L1LB2
AC1Q29EZ
ACon0_000082
ACon1_000297
AI3-52939
Adasone
Ancortone
Apo-Prednisone
Apo-prednisone
BPBio1_000323
BRD-K85883481-001-04-2
BSPBio_000293
Betapar
Bicortone
Bio-0649
C07370
C21H26O5
CCRIS 2646
CHEBI:8382
CHEMBL635
CID5865
CPD001227202
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
DB00635
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta E.
Delta-Cortelan
Delta-Dome
Delta-cortelan
Delta-cortisone
Delta-cortone
Delta-dome
Deltacortene
Deltacortisone
Deltacortone
Deltasone
Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone
Deltison
Deltisona
Deltisone
Deltra
Di-Adreson
Diadreson
EINECS 200-160-3
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fernisone
Fiasone
HMS1568O15
HMS2090J13
HSDB 3168
Hostacortin
In-Sone
Incocortyl
 
Juvason
Kortancyl
LMST02030180
LS-1325
Liquid Pred
Lisacort
Lodotra
MEGxm0_000443
MLS001061265
MLS001304073
MLS001335907
MLS001335908
MLS002154191
MLS002207083
Me-Korti
Metacortandracin
Meticorten
Meticorten (Veterinary)
Metrevet (Veterinary)
MolPort-001-740-041
NCGC00090766-01
NCGC00090766-02
NCGC00090766-03
NCI-C04897
NCI60_000008
NSC 10023
NSC10023
Nisona
Nizon
Novoprednisone
Nurison
Orasone
Origen Prednisone
P1276
P6254_SIGMA
PRD
Panafcort
Panasol
Paracort
Parmenison
Pehacort
Precort
Predeltin
Prednicen-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Prednison
Prednisona
Prednisona [INN-Spanish]
Prednisone
Prednisone Intensol
Prednisone [INN:BAN]
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Prestwick0_000077
Prestwick1_000077
Prestwick2_000077
Prestwick3_000077
Prestwick_405
Pronison
Pronisone
Rectodelt
Retrocortine
S1622_Selleck
SAM002264641
SK-Prednisone
SMR000718760
SMR001227202
SPBio_002214
Servisone
Sone
Sterapred
Supercortil
U 6020
UNII-VB0R961HZT
Ultracorten
Ultracortene
WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ
Winpred
Wojtab
ZINC03875357
Zenadrid
Zenadrid (veterinary)
Zenadrid [veterinary]
delta cortelan
delta(sup 1)-Cortisone
delta(sup 1)-Dehydrocortisone
delta-1-Cortisone
delta-1-Dehydrocortisone
delta-Cortisone
delta-Cortone
9
LenograstimapprovedPhase 4, Phase 3, Phase 2, Phase 11202135968-09-1
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
 
Granulocyte colony stimulating factor 3 (CHO cell derived)
Granulocyte colony-stimulating factor lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
10
ThiotepaapprovedPhase 4, Phase 2, Phase 121652-24-45453
Synonyms:
 
Thioplex
11
Doxorubicinapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1171423214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
12
rituximabapprovedPhase 4, Phase 3, Phase 1, Phase 2, Early Phase 11654174722-31-710201696
Synonyms:
AntiCD20
IDEC-102
IDEC-C2B8
 
Ig gamma-1 chain C region
MabThera
Mabthera
Rituxan
rituximab
13
Vincristineapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 19042068-78-2, 57-22-75978
Synonyms:
22-Oxovincaleukoblastin
22-Oxovincaleukoblastine
28379-27-3
57-22-7
AC1L1LJC
C07204
C46H56N4O10
CCRIS 5763
CHEBI:28445
CID5978
D08679
DB00541
EINECS 200-318-1
HMS2090E19
HSDB 3199
Indole alkaloid
LCR
LS-228
Leurocristine
Lilly 37231 (1:1 sulfate salt)
Liposomal Vincristine
Marqibo
NCGC00163700-01
NCI-C04864
NCI60_026703
NSC-67574
Onco TCS
 
Oncovin
Oncovin (1:1 sulfate salt)
Oncovine
Tecnocris
Tecnocris (TN)
UNII-5J49Q6B70F
VCR
VIN
Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine
Vincasar
Vincasar (1:1 sulfate salt)
Vincasar PFS
Vincrex
Vincrex (1:1 sulfate salt)
Vincristin
Vincristina
Vincristina [DCIT]
Vincristine (INN)
Vincristine Sulfate
Vincristine Sulfate PFS
Vincristine [INN:BAN]
Vincristinum
Vincristinum [INN-Latin]
Vincrstine
Vincrystine
Vinkristin
Z-D-Val-Lys(Z)-OH
vincristine
14
Cyclophosphamideapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1282950-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
15
DoxilApproved June 1999Phase 4, Phase 3, Phase 2, Phase 1171431703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
16Prednisolone acetatePhase 4, Phase 3, Phase 2, Phase 11153
17Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 122776
18Prednisolone phosphatePhase 4, Phase 3, Phase 2, Phase 11153
19Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 110884
20Neuroprotective AgentsPhase 4, Phase 3, Phase 2, Phase 11672
21ImmunoglobulinsPhase 4, Phase 3, Phase 1, Phase 2, Early Phase 16045
22Methylprednisolone HemisuccinatePhase 4, Phase 3, Phase 2, Phase 11153
23AntibodiesPhase 4, Phase 3, Phase 1, Phase 2, Early Phase 16045
24Antibodies, MonoclonalPhase 4, Phase 3, Phase 1, Phase 2, Early Phase 13795
25Etoposide phosphatePhase 4, Phase 3, Phase 2, Phase 1, Early Phase 11232
26Protective AgentsPhase 4, Phase 3, Phase 2, Phase 17190
27Prednisolone hemisuccinatePhase 4, Phase 3, Phase 2, Phase 11153
28Antirheumatic AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 110627
29Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 112770
30AntiemeticsPhase 4, Phase 3, Phase 2, Phase 13888
31Anti-Inflammatory AgentsPhase 4, Phase 3, Phase 2, Phase 110355
32Antineoplastic Agents, AlkylatingPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14474
33Antilymphocyte SerumPhase 4, Phase 2, Phase 1399
34Antibiotics, AntitubercularPhase 4, Phase 3, Phase 2, Phase 16972
35Methylprednisolone acetatePhase 4, Phase 3, Phase 2, Phase 11153
36Alkylating AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14694
37Antimitotic AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 15498
38Topoisomerase InhibitorsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14945
39Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 112778
40Antineoplastic Agents, HormonalPhase 4, Phase 3, Phase 2, Phase 15407
41Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 112767
42glucocorticoidsPhase 4, Phase 3, Phase 2, Phase 14920
43HormonesPhase 4, Phase 3, Phase 2, Phase 113979
44Autonomic AgentsPhase 4, Phase 3, Phase 2, Phase 19774
45Gastrointestinal AgentsPhase 4, Phase 3, Phase 2, Phase 18109
46Antineoplastic Agents, PhytogenicPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 15420
47
Amoxicillinapproved, vet_approvedPhase 344126787-78-033613, 2171
Synonyms:
(-)-6-(2-Amino-2-(P-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo-(3.2.0)heptane-2-carboxylic acid
(2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
26787-78-0
33911-69-2
34642-77-8 (mono-hydrochloride salt)
4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-amino-2-(p-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-, D- (8CI)
6-(D-(-)-alpha-Amino-p-hydroxyphenylacetamido)penicillanic acid
6-(D-(-)-p-Hydroxy-alpha-aminobenzyl)penicillin
6-(P-Hydroxy-alpha-aminophenylacetamido)penicillanic acid
6-(a-Amino-4-hydroxyphenylacetamido)penicillanic acid
6-(p-Hydroxy-alpha-aminophenylacetamido)penicillanic acid
6-(p-hydroxy-α-aminophenylacetamido)penicillanic acid
6-[[Amino(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 9CI
61336-70-7 (TRIHYDRATE)
6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carbonyl
6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carboxylic acid
71447-36-4
81030-75-3
AC-12263
AC1L1PY2
AMC
AMOXICILLIN CRYSTALLINE
AMOXICILLIN PEDIATRIC
AMPC
AUGMENTIN '125'
AUGMENTIN '200'
AUGMENTIN '250'
AUGMENTIN '400'
AUGMENTIN '500'
AUGMENTIN '875'
AUGMENTIN ES-600
AX
Actimoxi
Almodan
Ambap26787-78-0
Amix
Amoclen
Amolin
Amopen
Amopenixin
Amoram
Amox
Amox 250 Cap 250mg
Amox 500 Cap 500mg
Amox S 125 Sus 125mg/5ml
Amox S 250 Sus 250mg/5ml
Amoxi
Amoxi-Mast
Amoxi-mast
Amoxibiotic
Amoxicaps
Amoxicilina
Amoxicilina [INN-Spanish]
Amoxicillin (INN)
Amoxicillin (TN)
Amoxicillin (anhydrous)
Amoxicillin (inn)
Amoxicillin Trihydrate
Amoxicillin and clavulanate potassium
Amoxicillin anhydrous
Amoxicillin pediatric
Amoxicillin trihydrate
Amoxicillin(usan)
Amoxicilline
Amoxicilline [INN-French]
Amoxicilline [INN]
Amoxicilline [inn]
Amoxicillinum
Amoxicillinum [INN-Latin]
Amoxid
Amoxiden
Amoxil
Amoxivet
Amoxycillin
Amoxycillin Trihydrate
Amoxycillin trihydrate
Amoxycillin, BAN
Amoxymed
Amrit
Anemolin
Apo-Amoxi
Apo-Amoxi Cap 250mg
Apo-Amoxi Cap 500mg
Apo-Amoxi Pwr for Susp 125mg/5ml
Apo-Amoxi Pwr for Susp 250mg/5ml
Apo-amoxi
Apo-amoxi sugar free
Aspenil
BL-P 1410
BLP 1410
BPBio1_000499
BRD-K55044200-001-03-9
BRL 2333
BRL-2333
BSPBio_000453
 
Biomox
Bristamox
C06827
CHEBI:2676
CHEBI:53712
CHEMBL1082
CID33613
CPD000058707
Cemoxin
Clamoxyl
Clamoxyl (SKB)
D-(-)-alpha-Amino-p-hydroxybenzyl penicillin
D-(-)-alpha-Amino-p-hydroxybenzylpenicillin
D-(alpha-Amino-p-hydroxybenzyl)penicillin
D-2-Amino-2-(4-hydroxyphenyl)acetamidopenicillanic acid
D-Amoxicillin
D07452
DB01060
Delacillin
DisperMox
Dispermox
EINECS 248-003-8
Efpenix
Flemoxin
Galenamox
Gen-Amoxicillin 250mg
Gen-Amoxicillin 500mg
HMS1569G15
HSDB 3204
Hiconcil
Histocillin
Hydroxyampicillin
Ibiamox
Imacillin
LS-149721
Lamoxy
Larotid
MLS000028632
MLS002222248
Metafarma capsules
Metifarma capsules
MolPort-003-981-182
MolPort-005-933-687
Moxacin
Moxal
Moxatag
NCGC00179554-01
NSC 277174
NSC277174
Novamoxin Cap 250mg
Novamoxin Cap 500mg
Novamoxin Sus 125mg/5ml
Novamoxin Sus 250mg/5ml
Nu-Amoxi Cap 250mg
Nu-Amoxi Cap 500mg
Nu-Amoxi Sus 125/5ml
Nu-Amoxi Sus 250mg/5ml
Ospamox
P-Hydroxyampicillin
PHL-amoxicillin
PMS-amoxicillin
Pamoxicillin
Piramox
Polymox
Prestwick0_000357
Prestwick1_000357
Prestwick2_000357
Prestwick3_000357
Prestwick_713
Prevpac
Pro Amox Pwr for Oral Susp 125mg/5ml
Pro Amox-250 Cap 250mg
Pro Amox-500 Cap 500mg
Pro-Amox-250 Orl Sus 250mg/5ml
R-Hydroxyampicillin
Rimoxallin
Ro 10-8756
Robamox
SAM002264592
SMR000058707
SPBio_002374
Sauracillin
Sawamox PM
Sumox
Tolodina
Trimox
Unicillin
Utimox
Vetramox
Wymox
Zimox
alpha-Amino-p-hydroxybenzylpenicillin
alpha-amino-P-Hydroxybenzylpenicillin
amoxicillanyl
amoxicillin
p-Hydroxyampicillin
α-amino-p-hydroxybenzylpenicillin
48
OfloxacinapprovedPhase 322582419-36-14583
Synonyms:
( -)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)(1,4)benzoxazin-6-carbonsaeure
(+-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperaz inyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7- -oxo-7H-pyrido(1,2,3-de)- -1,4-benzoxazine-6-carboxylic acid
(+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid
(+/-)-Floxin
118120-51-7 (hydrochloride)
33703_FLUKA
33703_RIEDEL
8-Fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid
82419-36-1
83380-47-6
85344-55-4
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid
AB00513820
AC-7616
AC1L1IHM
AKOS001033517
BB_SC-1252
BPBio1_000345
BRD-A24228527-001-05-9
BRN 3657947
BSPBio_000313
BSPBio_003117
Bactocin
C07321
C18H20FN3O4
CCRIS 5233
CHEBI:7731
CHEMBL4
CID4583
CPD000058192
D00453
DB01165
DEXTROFLOXACINE
DL 8280
DL-8280
DL-8280, HOE-280, Exocin, Flobacin, Floxin, Floxil, Monoflocet, Ofloxacin
Danoflox
DivK1c_000721
EU-0100904
Effexin
Exocin
Exocine
FLOXIN IN DEXTROSE 5%
FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER
Flobacin
Flodemex
Flotavid
Flovid
Floxal
Floxil
Floxin
Floxin (TN)
Floxin otic
Floxstat
Fugacin
HMS1568P15
HMS1921H12
HMS2090F07
HMS2092B10
HMS502E03
HOE 280
Hoe-280
I06-0112
I06-0380
IDI1_000721
Inoflox
KBio1_000721
KBio2_001666
KBio2_004234
KBio2_006802
KBio3_002617
KBioGR_000667
KBioSS_001666
Kinflocin
Kinoxacin
LS-133259
Liflox
Lopac0_000904
Loxinter
MLS000028749
MLS001074203
Marfloxacin
Medofloxine
Mergexin
MolPort-000-422-241
MolPort-000-873-068
NCGC00015772-02
NCGC00015772-10
 
NCGC00094219-01
NCGC00094219-02
NCGC00094219-03
NCGC00094219-04
NCGC00094219-05
NCGC00094219-06
NCGC00178284-01
NCGC00178284-02
NINDS_000721
NSC727071
Novecin
Nufafloqo
O 8757
O-Flox
O8757_SIGMA
OFLX
OFX
ORF 18489
ORF-28489
Obide
Occidal
Ocuflox
Ofcin
Oflin
Oflocee
Oflocet
Oflocin
Oflodal
Oflodex
Oflodura
Oflox
Ofloxacin (JP15/USP/INN)
Ofloxacin Otic
Ofloxacin [USAN:BAN:INN:JAN]
Ofloxacin, (S)-Isomer
Ofloxacina
Ofloxacina [DCIT]
Ofloxacine
Ofloxacine [French]
Ofloxacino
Ofloxacino [Spanish]
Ofloxacinum
Ofloxacinum [Latin]
Ofloxin
Ofus
Onexacin
Operan
Oprea1_242882
Orocin
Otonil
Oxaldin
PT 01
Pharflox
Praxin
Prestwick0_000237
Prestwick1_000237
Prestwick2_000237
Prestwick3_000237
Puiritol
Qinolon
Qipro
Quinolon
Quotavil
Rilox
Ru-43280
S1463_Selleck
SAM002264629
SMR000058192
SPBio_001387
SPBio_002234
SPECTRUM1502044
STK256723
Sinflo
Spectrum2_001464
Spectrum3_001499
Spectrum4_000324
Spectrum5_001063
Spectrum_001186
Tabrin
Taravid
Tariflox
Tarivid
Telbit
Tructum
UNII-A4P49JAZ9H
Uro Tarivid
Viotisone
Visiren
WP-0405
XED
Zanocin
ofloxacin
49
Ketamineapproved, vet_approvedPhase 35286740-88-13821
Synonyms:
(+-)-Ketamine
(+/-)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone
(+/-)-2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone
(+/-)-Ketamine
(-)-Ketamine
(S)-(-)-Ketamine
(S)-Ketamine
(±)-ketamine
100477-72-3
2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone
2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone
2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one
2-(Methylamino)-2-(2-chlorophenyl)cyclohexanone
2-(methylamino)-2-(2-chlorophenyl)cyclohexanone
2-(o-Chlorophenyl)-2-(methylamino)-cyclohexanone
2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone
2-(o-chlorophenyl)-2-(methylamino)-cyclohexanone
33643-45-7
6740-88-1
79499-51-7
AC1L1GSH
AC1Q40UR
AKOS001053247
BRN 2216965
C07525
C13H16ClNO
CHEBI:138833
CHEBI:6121
CHEMBL742
CI 581 base
CI-581
CID3821
CLSTA 20
Calypsol
Cetamina
Cetamina [INN-Spanish]
Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)- (9CI)
Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (+-)- (9CI)
Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+/-)- (8CI)
D08098
DB01221
DEA No. 7285
 
DL-ketamine
DivK1c_000217
EINECS 229-804-1
Esketamine
Green
IDI1_000217
KBio1_000217
KETAMINE
KETAMINE HCL
Ketaject
Ketalar
Ketalar base
Ketamina
Ketamine (INN)
Ketamine Base
Ketamine HCL
Ketamine [INN:BAN]
Ketaminum
Ketaminum [INN-Latin]
Ketanest
Ketoject
Ketolar
L-Ketamine
LS-57301
MLS001331674
MolPort-001-838-070
NCGC00159480-02
NCGC00159480-03
NINDS_000217
NMDA
NSC 70151
NSC70151
SMR000238141
Special K
Special K [street name]
Special k
T385
Tekam
Tekam (TN)
UNII-690G0D6V8H
dl-Ketamine
ketamine
l-Ketamine
50
Levofloxacinapproved, investigationalPhase 3225100986-85-4149096
Synonyms:
(−
(-)-(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyridol[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate
(-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7Hpyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate
(-)-Ofloxacin
(3S)-(-)-9-Fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid
(3S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid
(R)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(R)-isomer
(S)-(-)-9-Fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
(S)-(-)-Ofloxacin
(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(S)-Ofloxacin
)-Ofloxacin
100986-85-4
100986-86-5
28266_FLUKA
28266_SIGMA
AC-7593
AC1L3YF8
Aeroquin
Ambap100986-85-4
BRD-K09471561-001-06-7
BSPBio_002689
C07660
C18H20FN3O4
C18H20FN3O4.H2O
CCRIS 4073
CCRIS 4074
CHEMBL33
CID149096
CPD000466387
Cravit
Cravit (TN)
Cravit Ophthalmic
D08120
DB01137
DR 3354
DR-3355
DR-3355: L-isomer of ofloxacin
DR3355
Elequine
Floxacin
Floxel
Floxin
HMS1922J07
HMS2051G04
HMS2090O10
HMS2093E18
HR 355
HR-355
Iquix
KBio2_002199
KBio2_004767
KBio2_007335
KBio3_001909
 
KBioGR_001605
KBioSS_002199
L-Ofloxacin
L-ofloxacin
L0193
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER
LEVOFLOXACIN
LFX
LS-133260
LS-171761
LVX
Leroxacin
Lesacin
Levaquin
Levofloxacin
Levofloxacin (INN)
Levofloxacin [USAN:INN:JAN]
Levofloxacin hydrate
Levofloxacin tablet, suspension or intravenous
Levofloxacine
Levofloxacine [INN-French]
Levofloxacino
Levofloxacino [INN-Spanish]
Levofloxacinum
Levofloxacinum [INN-Latin]
Levokacin
Levox
Levoxacin
MLS000759524
MLS001165709
MLS001423977
MP-376
MolPort-002-885-835
Mosardal
NCGC00178529-01
Nofaxin
Ofloxacin
Ofloxacin S-(-)-form
Oftaquix
Quixin
R-Ofloxacin
RWJ 25213-097
RWJ-25213
Reskuin
S-(-)-Ofloxacin
S1940_Selleck
SAM001246758
SMR000466387
SPBio_001891
SPECTRUM1504260
Spectrum2_001676
Spectrum3_000995
Spectrum4_001123
Spectrum5_001438
Spectrum_001719
Tavanic
Volequin
d-Levofloxacin

Interventional clinical trials:

(show top 50)    (show all 1165)
idNameStatusNCT IDPhase
1Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PETUnknown statusNCT00188149Phase 4
2Doxorubicin Pharmacokinetics and Response in Non Hodgkin's LymphomaCompletedNCT00969462Phase 4
3Bone Marrow Transplantation in Treating Patients With Hematologic CancerCompletedNCT00003398Phase 4
4Surgery Alone, Surgery With Cyclophosphamide, Vinblastine, and Prednisolone (CVP), or CVP Alone in Treating Young Patients With Stage IA or Stage IIA Nodular Lymphocyte-Predominant Hodgkin LymphomaRecruitingNCT01088750Phase 4
5Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary LymphomaRecruitingNCT02526823Phase 4
6A Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin LymphomaActive, not recruitingNCT01990534Phase 4
7Combination Chemotherapy Given With Radiation Therapy or Radiation Therapy Alone in Treating Patients With Early-Stage Hodgkin's DiseaseUnknown statusNCT00002987Phase 3
8Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's LymphomaUnknown statusNCT00816959Phase 3
9Combination Chemotherapy and Peripheral Stem Cell Transplant in Treating Patients With Relapsed Hodgkin's LymphomaUnknown statusNCT00025636Phase 3
10Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's LymphomaUnknown statusNCT00003924Phase 3
11Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin's LymphomaUnknown statusNCT00041210Phase 3
12Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin LymphomaUnknown statusNCT00678327Phase 3
13Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and NeutropeniaUnknown statusNCT00020865Phase 3
14Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic PainUnknown statusNCT01316744Phase 3
15Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile NeutropeniaUnknown statusNCT00445497Phase 3
16Exercise During Chemotherapy for Patients With Hematological MalignanciesUnknown statusNCT00884364Phase 3
17Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD ChemotherapyCompletedNCT00038558Phase 3
18Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's DiseaseCompletedNCT00002561Phase 3
19Treatment of Advanced Hodgkin's Disease (Stages IIB-III-IV)CompletedNCT00443677Phase 3
20Combination Chemotherapy in Treating Patients With Advanced Hodgkin's DiseaseCompletedNCT00003421Phase 3
21Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's DiseaseCompletedNCT00025259Phase 3
22Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's DiseaseCompletedNCT00002827Phase 3
23Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's LymphomaCompletedNCT01251107Phase 3
24Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's DiseaseCompletedNCT00005578Phase 3
25Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's LymphomaCompletedNCT00070187Phase 2, Phase 3
26A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)CompletedNCT01034163Phase 3
27Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's LymphomaCompletedNCT00433433Phase 3
28Combination Chemotherapy in Treating Young Patients With Hodgkin's LymphomaCompletedNCT00433459Phase 3
29Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of ThrombocytopeniaCompletedNCT00039910Phase 3
30Study of a Treatment Driven by Early PET Response to a Treatment Not Monitored by Early PET in Patients With AA Stage 3-4 or 2B HLCompletedNCT01358747Phase 3
31Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's DiseaseCompletedNCT00003414Phase 3
32HD11 for Intermediate StagesCompletedNCT00264953Phase 3
33HD12 for Advanced StagesCompletedNCT00265031Phase 3
34HD10 for Early StagesCompletedNCT00265018Phase 3
35A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma).CompletedNCT00838357Phase 3
36Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose TherapyCompletedNCT01085058Phase 2, Phase 3
37Tacrolimus/Sirolimus/Methotrexate Versus Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With LymphomaCompletedNCT00928018Phase 3
38A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing ChemotherapyCompletedNCT00261677Phase 3
39Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell CountCompletedNCT00003805Phase 3
40Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem CellsCompletedNCT00398411Phase 3
41Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-dose ChemotherapyCompletedNCT00041665Phase 3
42Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic MalignanciesCompletedNCT01188798Phase 3
43Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late ComplicationsCompletedNCT00799461Phase 3
44Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative TherapyCompletedNCT00469729Phase 2, Phase 3
45Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer PatientsCompletedNCT00003938Phase 3
46St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for CancerCompletedNCT00005805Phase 3
47Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a CatheterCompletedNCT00006083Phase 3
48Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic CancerCompletedNCT00265837Phase 3
49Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or LymphomaCompletedNCT00005590Phase 3
50Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer TreatmentCompletedNCT00008359Phase 3

Search NIH Clinical Center for Hodgkin Lymphoma

Inferred drug relations via UMLS67/NDF-RT45:

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hodgkin Lymphoma cell therapies at LifeMap Discovery.

Genetic Tests for Hodgkin Lymphoma

About this section

Genetic tests related to Hodgkin Lymphoma:

id Genetic test Affiliating Genes
1 Hodgkin Lymphoma26 24 KLHDC8B

Anatomical Context for Hodgkin Lymphoma

About this section

MalaCards organs/tissues related to Hodgkin Lymphoma:

35
B cells, Bone, Bone marrow, T cells, Lymph node, Liver, Kidney

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Hodgkin Lymphoma:
id TissueAnatomical CompartmentCell Relevance
1 BloodHematopoietic Bone MarrowHematopoietic Stem Cells Potential therapeutic candidate
2 BloodPeripheral BloodMature B-Cells Affected by disease

Animal Models for Hodgkin Lymphoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Hodgkin Lymphoma:

40
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000537910.1ALK, BCL2, BCL6, BRAF, LTA, PRDM1
2MP:00053979.1BCL2, BCL6, BRAF, CSF3, LTA, LY75
3MP:00053878.7BCL2, BCL6, BRAF, CSF3, FSCN1, LTA
4MP:00107688.5ALK, BCL2, BCL6, BCL7A, BRAF, FSCN1

Publications for Hodgkin Lymphoma

About this section

Articles related to Hodgkin Lymphoma:

(show top 50)    (show all 1705)
idTitleAuthorsYear
1
Hodgkin lymphoma mimicking lung abscess. (28007734)
2016
2
A strong host response and lack of MYC expression are characteristic for diffuse large B cell lymphoma transformed from nodular lymphocyte predominant Hodgkin lymphoma. (27708232)
2016
3
Hodgkin Lymphoma Variant of Richter Transformation: Morphology, EBV status, Clonality and Survival Analysis-with Comparison to Hodgkin-like Lesion. (27184478)
2016
4
Diagnostic Utility of PAX5 in Hodgkin and Non-Hodgkin Lymphoma: A Study from Northern India. (27656544)
2016
5
Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation. (27183095)
2016
6
Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma. (26004934)
2015
7
MEF2B mutations in non-Hodgkin lymphoma dysregulate cell migration by decreasing MEF2B target gene activation. (26245647)
2015
8
CD68 staining correlates with the size of residual mass but not with survival in classical Hodgkin lymphoma. (25204373)
2015
9
The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin Lymphoma. (25382792)
2014
10
Dietary patterns and the risk of non-Hodgkin lymphoma. (23659580)
2013
11
Primary non-Hodgkin lymphoma of the bladder. (24369199)
2013
12
Atrazine and nitrate in public drinking water supplies and non-hodgkin lymphoma in nebraska, USA. (23515852)
2013
13
Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma. (23256748)
2013
14
The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). (24100447)
2013
15
Angiokeratoma corporis diffusum in a patient with Hodgkin lymphoma: a new paraneoplastic skin manifestation? (23278357)
2013
16
Non-Hodgkin lymphoma as an uncommon cause of acute heart failure. (23503834)
2013
17
Treatment of nodular lymphocyte-predominant Hodgkin lymphoma-"do no harm". (24472810)
2013
18
Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. (24352795)
2013
19
90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial. (23547079)
2013
20
The association of hepatitis B virus infection with B-cell non-Hodgkin lymphoma - a review. (22432084)
2012
21
Does "in situ lymphoma" occur as a distinct step in the development of nodular lymphocyte-predominant Hodgkin lymphoma? (21732334)
2012
22
Non-hodgkin lymphoma in a child with schimke immuno-osseous dysplasia. (23359635)
2011
23
Sexual well-being among survivors of non-Hodgkin lymphoma. (21875831)
2011
24
Progressive transformation of germinal centers and Hodgkin lymphoma: more insights but maybe more confusion? (21888616)
2011
25
Oropharyngeal tularemia mimicking tumoral relapse in a patient with Hodgkin lymphoma in remission. (21853659)
2011
26
KLF4 is a tumor suppressor in B-cell non-Hodgkin lymphoma and in classic Hodgkin lymphoma. (20519630)
2010
27
Association analysis between the Cdc6 G1321A polymorphism and the risk for non-Hodgkin lymphoma and hepatocellular carcinoma. (19101572)
2009
28
Organochlorine exposure, immune gene variation, and risk of non-Hodgkin lymphoma. (19066394)
2009
29
A 19-year follow-up of a patient with type 3 ectrodactyly-ectodermal dysplasia-clefting syndrome who developed non-Hodgkin lymphoma. (19716498)
2009
30
Non-Hodgkin lymphoma (NHL) in children with Nijmegen Breakage syndrome (NBS). (18937313)
2009
31
Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma. (19383901)
2009
32
On the biosynthesis and biological role of eoxins and 15-lipoxygenase-1 in airway inflammation and Hodgkin lymphoma. (19130894)
2009
33
Polymorphic variation in NFKB1 and other aspirin-related genes and risk of Hodgkin lymphoma. (19223558)
2009
34
Social inequality and incidence of and survival from Hodgkin lymphoma, non-Hodgkin lymphoma and leukaemia in a population-based study in Denmark, 1994-2003. (18657412)
2008
35
Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. (18541724)
2008
36
The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs. (18949621)
2008
37
Paraneoplastic lumbosacral axonal polyradiculopathy preceding the diagnosis of nodular lymphocyte predominant Hodgkin lymphoma: a case report. (18720211)
2008
38
Soft tissue non-Hodgkin lymphoma of shoulder in a HIV patient: a report of a case and review of the literature. (18939988)
2008
39
The use of galiximab in non-Hodgkin lymphoma. (18854281)
2008
40
Beyond the lymphocyte predominant cell: CD4+CD8+ T-cells in nodular lymphocyte predominant Hodgkin lymphoma. (18949610)
2008
41
HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma. (17630352)
2007
42
High expression of several tyrosine kinases and activation of the PI3K/AKT pathway in mediastinal large B cell lymphoma reveals further similarities to Hodgkin lymphoma. (17375124)
2007
43
Polymorphisms in innate immunity genes and risk of non-Hodgkin lymphoma. (16740140)
2006
44
Risk of non-Hodgkin lymphoma (NHL) in relation to germline variation in DNA repair and related genes. (16857995)
2006
45
Inhibitory effect of triptolide on lymph node metastasis in patients with non-Hodgkin lymphoma by regulating SDF-1/CXCR4 axis in vitro. (17049119)
2006
46
A putative exonic splicing polymorphism in the BCL6 gene and the risk of non-Hodgkin lymphoma. (16264183)
2005
47
Intensive sequential chemotherapy with hematopoietic growth factor support for non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus. (14770420)
2004
48
Antibody-targeted therapy: a paradigm of innovative treatment strategies in indolent and aggressive B-cell non-Hodgkin lymphoma. (15548997)
2004
49
Therapy-related acute leukemia associated with involvement of 11q23 after high grade non-Hodgkin lymphoma. (9573684)
1998
50
Immunohistochemistry of Hodgkin and non-Hodgkin lymphomas with emphasis on the diagnostic significance of the BNH9 antibody reactivity with anaplastic large cell (CD30 positive) lymphomas. (1330287)
1992

Variations for Hodgkin Lymphoma

About this section

Clinvar genetic disease variations for Hodgkin Lymphoma:

5
id Gene Variation Type Significance SNP ID Assembly Location
1KLHDC8BNM_173546.2(KLHDC8B): c.-158C> TSNVPathogenicrs387906223GRCh37Chr 3, 49209095: 49209095

Cosmic variations for Hodgkin Lymphoma:

8 (show all 16)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM5416033NFKBIEhaematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphomac.782+5G>Ap.?15
2COSM10894TP53haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphomac.670G>Ap.E224K15
3COSM35970TNFAIP3haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphomac.1421C>Ap.T474N15
4COSM581NRAShaematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphomac.181C>Gp.Q61E15
5COSM566NRAShaematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphomac.35G>Tp.G12V15
6COSM574NRAShaematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphomac.38G>Tp.G13V15
7COSM564NRAShaematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphomac.35G>Ap.G12D15
8COSM44571TP53haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphomac.581T>Gp.L194R15
9COSM499HRAShaematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphomac.182A>Gp.Q61R15
10COSM35909TNFAIP3haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphomac.254G>Ap.W85*15
11COSM35907TNFAIP3haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphomac.2209C>Ap.Q737K15
12COSM35969TNFAIP3haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphomac.503G>Ap.W168*15
13COSM562NRAShaematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphomac.34G>Tp.G12C15
14COSM35908TNFAIP3haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphomac.2251G>Ap.E751K15
15COSM586NRAShaematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphomac.183A>Cp.Q61H15
16COSM35913TNFAIP3haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphomac.905T>Cp.L302P15

Copy number variations for Hodgkin Lymphoma from CNVD:

6 (show top 50)    (show all 204)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1154341115570986115748025Copy numberHodgkin''s lymphoma
2181481144224941245407169Copy numberHodgkin''s lymphoma
3213621158258490227249364Copy numberHodgkin''s lymphoma
4297811235850830237390561Copy numberHodgkin''s lymphoma
5299221238038528245407169Copy numberHodgkin''s lymphoma
6353901629370018251002Copy numberHodgkin''s lymphoma
737216187388008120033702Copy numberHodgkin''s lymphoma
8374601914681316679690Copy numberHodgkin''s lymphoma
93849110102895110124244273Copy numberHodgkin''s lymphoma
104019710125057756126954997Copy numberHodgkin''s lymphoma
114063710131215760132635356Copy numberHodgkin''s lymphoma
124162010214400133778456Copy numberHodgkin''s lymphoma
1341883102524097436004765Copy numberHodgkin''s lymphoma
14435711046999355135111152Copy numberHodgkin''s lymphoma
1543572104699935548101366Copy numberHodgkin''s lymphoma
1643573104699935549467140Copy numberHodgkin''s lymphoma
1744594106009535578914295Copy numberHodgkin''s lymphoma
18447841062776748346525Copy numberHodgkin''s lymphoma
1945116106755176178914295Copy numberHodgkin''s lymphoma
2046267107968795285721525Copy numberHodgkin''s lymphoma
21467881086278375101096913Copy numberHodgkin''s lymphoma
224926011104569097133732868Copy numberHodgkin''s lymphoma
235017711115327798134437143Copy numberHodgkin''s lymphoma
24524931117822735140556Copy numberHodgkin''s lymphoma
2557515116356013972573784Copy numberHodgkin''s lymphoma
2657783116480000075000000GainHodgkin''s lymphoma
27585061168129639134437143Copy numberHodgkin''s lymphoma
28602541184447402105734987Copy numberHodgkin''s lymphoma
29606771189286313104569095Copy numberHodgkin''s lymphoma
306433512126737931132373208Copy numberHodgkin''s lymphoma
31652261215253416164790Copy numberHodgkin''s lymphoma
326522712152534525774777Copy numberHodgkin''s lymphoma
336781712449038444739500Copy numberHodgkin''s lymphoma
3467821124500000056400000GainHodgkin''s lymphoma
3568783125150000063100000GainHodgkin''s lymphoma
3668979125241712660370345Copy numberHodgkin''s lymphoma
3769531125562789956288135Copy numberHodgkin''s lymphoma
38700951258245748132373208Copy numberHodgkin''s lymphoma
3970715126426372866931770Copy numberHodgkin''s lymphoma
4071442127000000082000000GainHodgkin''s lymphoma
41725631282669309120958351Copy numberHodgkin''s lymphoma
42752451318397782106691271Copy numberHodgkin''s lymphoma
43752461318397782114117460Copy numberHodgkin''s lymphoma
4475871132540000038500000LossHodgkin''s lymphoma
4575878132550000032200000LossHodgkin''s lymphoma
4679388137100000083000000LossHodgkin''s lymphoma
4783222141957080742171562Copy numberHodgkin''s lymphoma
4883386142038348953262838Copy numberHodgkin''s lymphoma
4983387142038348956623380Copy numberHodgkin''s lymphoma
50855581448879628106278173Copy numberHodgkin''s lymphoma

Expression for genes affiliated with Hodgkin Lymphoma

About this section
Search GEO for disease gene expression data for Hodgkin Lymphoma.

Pathways for genes affiliated with Hodgkin Lymphoma

About this section

Pathways related to Hodgkin Lymphoma according to GeneCards Suite gene sharing:

(show all 12)
idSuper pathwaysScoreTop Affiliating Genes
110.2BCL2, BRAF
29.9BCL2, BCL6, CASP10, PRDM1
39.8BCL6, PAX5, PRDM1, REL
4
Show member pathways
9.8BCL2, REL, TNFRSF8, TNFSF8
59.8BCL6, LTA, PAX5, PRDM1
69.8BCL2, CSF3, LTA, TNFSF8
7
Show member pathways
9.7BCL2, CASP10, LTA, TNFRSF8, TNFSF8
89.6BCL6, MS4A1, PAX5, PRDM1, TNFRSF8
9
Show member pathways
9.5BCL2, CASP10, LTA, NPM1, TNFRSF8, TNFSF8
10
Show member pathways
9.3ALK, BCL2, CSF3, LTA, RHOH, TNFRSF8
11
Show member pathways
9.3BCL2, CASP10, CSF3, LTA, RHOH, TNFRSF8
12
Show member pathways
9.2ALK, BCL2, BRAF, CASP10, CSF3, LTA

GO Terms for genes affiliated with Hodgkin Lymphoma

About this section

Biological processes related to Hodgkin Lymphoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1humoral immune responseGO:000695910.1BCL2, LTA, MS4A1, PAX5
2positive regulation of peptidyl-serine phosphorylationGO:003313810.0BCL2, BRAF, CSF3
3regulation of apoptotic processGO:00429819.6ALK, BCL2, BCL6, CASP10

Sources for Hodgkin Lymphoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet